VIENNA, Sept. 30 /PRNewswire/ -- Intarcia Therapeutics, Inc. today presented final results from its Phase 1b clinical study of ITCA 650 (DUROS® continuous delivery of exenatide) for the treatment of type 2 diabetes at the Annual Conference of the European Association for the Study of Diabetes in Vienna, Austria. Results of the study demonstrate substantial reductions in fasting plasma glucose (FPG) within 24 hours of the start of treatment and a sustained glucose lowering effect throughout the 28 day treatment period. Other important results from the study were significant reductions in postprandial glucose (PPG), HbA1c and body weight.
"The results from the ITCA 650 phase 1b study demonstrate the potential for DUROS continuous delivery of exenatide to improve the treatment of type 2 diabetes," said Kenneth L. Luskey, MD, VP Clinical Research at Intarcia. "ITCA 650 addresses some of the key limitations observed with other incretin mimetic therapies by eliminating the need for frequent self-injection, limiting the incidence and persistence of nausea and ensuring treatment compliance."
The phase 1b dose ranging study was conducted at multiple centers in the United States and evaluated a 28-day course of ITCA 650 treatment among patients with type 2 diabetes (10-12 patients/dose arm) on a stable treatment regimen of diet and exercise or treatment with metformin and/or thiazolidinediones. The study included 4 dose arms to which patients were randomized to receive 10 mcg/day, 20mcg/day, 40 mcg/day or 80 mcg/day exenatide for a 28 day treatment duration via a single insertion of ITCA 650. ITCA 650 therapy in this phase 1b trial was administered for the full course of treatment with a single insertion of the I
|SOURCE Intarcia Therapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved